Advances in immunotherapy have significantly altered the outlook for sRCC, with ongoing trials evaluating combinations of PD-1 inhibitors and VEGF-targeted TKIs (e.g., pembrolizumab plus axitinib, nivolumab plus cabozantinib) that may enhance immune responsiveness by modulating the tumor microenvironment [129]. This evidence concerns the gene VEGFA and neoplasm.